Therapeutic-dose heparin combined with antiplatelets in noncritically ill patients with COVID-19: a secondary analysis of a multiplatform randomized controlled trial

Therapeutic-dose heparin combined with antiplatelets in noncritically ill patients with COVID-19: a secondary analysis of a multiplatform randomized controlled trial

Background: Therapeutic-dose heparin improves outcomes in noncritically ill patients hospitalized for COVID-19. The effect of antiplatelet exposure in addition to therapeutic-dose heparin is unknown. Objectives: To evaluate the effect of antiplatelet exposure in addition to therapeutic-dose heparin...

Full description

Saved in:
Bibliographic Details
Main Authors: Sylvain A. Lother, Wen Teng, Olawale Ayilara, Brett L. Houston, Barret Rush, Srinivas Murthy, Jose C. Nicolau, Lindsay Bond, Alexis F. Turgeon, John C. Marshall, Jonathan Paul, Judith S. Hochman, Matthew D. Neal, Michael E. Farkouh, Joel Nkosi, Donald S. Houston, Charlotte A. Bradbury, Asher A. Mendelson, Ewan C. Goligher, Allan Garland, Robert Balshaw, Souradet Y. Shaw, Patrick R. Lawler, Yoav Keynan, Ryan Zarychanski
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
aspirin
clopidogrel
COVID-19
heparin
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S2475037925002171
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2475037925002171

Similar Items